EUSA Pharma (EUSA), a biopharmaceutical company focused on oncology and rare disease, announced that it has entered into a definitive agreement with Janssen Sciences Ireland UC, a subsidiary of Janssen R&D Ireland (Janssen) to acquire the global rights to SYLVANT® (siltuximab) for $115 million.
SYLVANT, discovered and developed by Janssen, is approved in more than 40 countries worldwide, including the United States, the European Union, the Republic of Korea and Canada, for the treatment of idiopathic multicentric Castleman’s disease (iMCD), a rare, life threatening and debilitating orphan condition. Idiopathic MCD is an inflammatory lymphoproliferative disorder, which causes the abnormal overgrowth of immune cells and shares many symptomatic and histological features with lymphoma.1 The disease can affect individuals at any age, with iMCD representing one-third to half of all multicentric Castleman’s disease (MCD). SYLVANT is the only approved treatment for iMCD in the United States and Europe.
Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. Headquartered in Hemel Hempstead, Hertford (UK), the company has commercial operations in the United States and Europe, and a wider distribution network in approximately 40 countries around the world.